Chronic renal allograft rejection: Pathophysiologic considerations

Kidney International

Volumn 68, Issue 1, 2005, Pages 1-13

  Joosten, Simone A ^a   Sijpkens, Yvo W J ^a   Van Kooten, Cees ^a   Paul, Leendert C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic allograft nephropathy; Chronic rejection; Humoral responses; Risk factors; Senescence

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ANTIGEN RECOGNITION; BLOOD VESSEL REACTIVITY; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DONOR; GLOMERULOPATHY; HISTOINCOMPATIBILITY; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; REPERFUSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENESCENCE; SENSITIZATION; SMOKING; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY;

CHRONIC DISEASE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION;

EID: 24944462903     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00376.x     Document Type: Article

References (153)

1. HARIHARAN S, JOHNSON CP, BRESNAHAN BA, et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605-612, 2000
2. PAUL LC: Chronic allograft nephropathy: An update. Kidney Int 56:783-793, 1999
3. HALLORAN PF: Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2:195-200, 2002
4. IVANYI B: Transplant capillaropathy and transplant glomerulopathy: Ultrastructural markers of chronic renal allograft rejection. Nephrol Dial Transplant 18:655-660, 2003
5. PAUL LC, HAYRY P, FOEGH M, et al: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 25:2022-2023, 1993
6. KASISKE BL, ANDANY MA, DANIELSON B: A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 39:762-768, 2002
7. MASSY ZA, GUIJARRO C, WIEDERKEHR MR, et al: Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int 49:518-524, 1996
8. MAUIYYEDI S, COLVIN RB: Pathology of kidney transplantation, chap. 24. in Kidney Transplantation, 5th ed., edited by Morris PJ, Oxford, W.B. Saunders Company, 2002, pp 343-376
9. FREESE P, SVALANDER CT, MOLNE J, et al: Chronic allograft nephropathy-biopsy findings and outcome. Nephrol Dial Transplant 16:2401-2406, 2001
10. NANKIVELL BJ, BORROWS RJ, FUNG CL, et al: The natural history of chronic allograft nephropathy. N Engl J Med 349:2326-2333, 2003
11. GRIMM PC, NICKERSON P, JEFFERY J, et al: Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 345:93-97, 2001
12. MARYNIAK RK, FIRST MR, WEISS MA: Transplant glomerulopathy: Evolution of morphologically distinct changes. Kidney Int 27:799-806, 1985
13. ANDRESDOTTIR MB, ASSMANN KJ, KOENE RA, et al: Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 32:582-588, 1998
14. SURI DL, TOMLANOVICH SJ, OLSON JL, et al: Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 35:674-680, 2000
15. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff Working Classification of Kidney Transplant Pathology. Kidney Int 44:411-422, 1993
16. SOLEZ K, BENEDIKTSSON H, CAVALLO T, et al: Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on Classification and Lesion Scoring in Renal Allograft Pathology. Transplant Proc 28:441-444, 1996
17. RACUSEN LC, SOLEZ K, COLVIN RB, et al: The Banff 97 Working Classification of Renal Allograft Pathology. Kidney Int 55:713-723, 1999
18. NICHOLSON ML, HARPER SJ, WHEATLEY TJ, et al: Renal transplant fibrosis: Histomorphometric assessment of early renal transplant biopsies for markers of chronic rejection. Transplant Proc 29:2793-2794, 1997
19. NANKIVELL BJ, FENTON-LEE CA, KUYPERS DR, et al: Effect of histological damage on long-term kidney transplant outcome. Transplantation 71:515-523, 2001
20. LINDHOLM A, OHLMAN S, ALBRECHTSEN D, et al: The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 56:307-315, 1993
21. VAN SAASE JL, VAN DER WOUDE FJ, THOROGOOD J, et al: The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 59:1280-1285, 1995
22. SIJPKENS YW, DOXIADIS II, DE FIJTER JW, et al: Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 56:1920-1927, 1999
23. MADDEN RL, MULHERN JG, BENEDETTO BJ, et al: Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transplant Int 13:344-350, 2000
24. MEIER-KRIESCHE HU, SCHOLD JD, SRINIVAS TR, et al: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378-383, 2004
25. HUMAR A, PAYNE WD, SUTHERLAND DE et al: Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 69:2357-2360, 2000
26. SHISHIDO S, ASANUMA H, NAKAI H, et al: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14:1046-1052, 2003
27. SIJPKENS YW, DOXIADIS II, MALLAT MJ, et al: Early versus late acute rejection episodes in renal transplantation. Transplantation 75:204-208, 2003
28. TAKEMOTO SK, CHO YW, GJERTSON DW: Transplant risks, in Clinical Transplants 1999, edited by Terasaki PI, Cecka JM, Los Angeles, Tissue Typing Laboratory, 1999, pp 325
29. MCKENNA RM, TAKEMOTO SK, TERASAKI PI: Anti-HLA antibodies after solid organ transplantation. Transplantation 69:319-326, 2000
30. SUSAL C, OPELZ G: Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 73:1269-1273, 2002
31. LEE PC, TERASAKI PI, TAKEMOTO SK, et al: All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74:1192-1194, 2002
32. PIAZZA A, POGGI E, BORRELLI L, et al: Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 71:1106-1112, 2001
33. SMITS JM, VAN HOUWELINGEN HC, DE MEESTER J, et al: Permanent detrimental effect of nonimmunological factors on long-term renal graft survival: A parsimonious model of time-dependency. Transplantation 70:317-323, 2000
34. TAKEMOTO SK, TERASAKI PI, GJERTSON DW et al: Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 343:1078-1084, 2000
35. OPELZ G: New immunosuppressants and HLA matching. Transplant Proc 33:467-468, 2001
36. MEIER-KRIESCHE HU, OJO AO, LEICHTMAN AB, et al: Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 71:398-401, 2001
37. KOO DD, WELSH KI, MCLAREN AJ, et al: Cadaver versus living donor kidneys: Impact of donor factors on antigen induction before transplantation. Kidney Int 56:1551-1559, 1999
38. GIRAL-CLASSE M, HOURMANT M, CANTAROVICH D, et al: Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 54:972-978, 1998
39. BOOM H, MALLAT MJ, DE FIJTER JW, et al: Delayed graft function influences renal function, but not survival. Kidney Int 58:859-866, 2000
40. BRADLEY BA: Rejection and recipient age. Transpl Immunol 10:125-132, 2002
41. RAIZ LR, KILTY KM, HENRY ML, et al: Medication compliance following renal transplantation. Transplantation 68:51-55, 1999
42. YOUNG CJ, GASTON RS: Renal transplantation in black Americans. N Engl J Med 343:1545-1552, 2000
43. FELDMAN HI, GAYNER R, BERLIN JA, et al: Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 11:1306-1313, 1996
44. FLECHNER SM, MODLIN CS, SERRANO DP, et al: Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 62:1235-1241, 1996
45. JOHNSON EM, CANAFAX DM, GILLINGHAM KJ, et al: Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplant 11:552-557, 1997
46. KAHAN BD, WELSH M, SCHOENBERG L, et al: Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 62:599-606, 1996
47. DE GEEST S, BORGERMANS L, GEMOETS H, et al: Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 59:340-347, 1995
48. SAYEGH MH: Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 56:1967-1979, 1999
49. WOMER KL, STONE JR, MURPHY B, et al: Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 12:2500-2506, 2001
50. KRIEGER NR, YIN DP, FATHMAN CG: CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 184:2013-2018, 1996
51. CHAPMAN TM, KEATING GM: Basiliximab: A review of its use as induction therapy in renal transplantation. Drugs 63:2803-2835, 2003
52. SAYEGH MH, TURKA LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338:1813-1821, 1998
53. HOLZKNECHT ZE, PLATT JL: The fine cytokine line between graft acceptance and rejection. Nat Med 6:497-498, 2000
54. NIIRO H, CLARK EA: Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2:945-956, 2002
55. MAK TW, SHAHINIAN A, YOSHINAGA SK, et al: Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat Immunol 4:765-772, 2003
56. HARADA H, SALAMA AD, SHO M, et al: The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 112:234-243, 2003
57. YAMADA AA, SAYEGH MH: The CD154-CD40 costimulatory pathway in transplantation. Transplantation 73:S36-S39. 2002
58. LASKOWSKI IA, PRATSCHKE J, WILHELM MJ, et al: Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 13:519-527, 2002
59. ENSMINGER SM, SPRIEWALD BM, WITZKE O, et al: Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 73:279-286, 2002
60. JOOSTEN SA, VAN KOOTEN C, PAUL LC: Pathogenesis of chronic allograft rejection. Transplant Int 16:137-145, 2003
61. HANCOCK WW, BUELOW R, SAYEGH MH, et al: Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 4:1392-1396, 1998
62. REGELE H, BOHMIG GA, HABICHT A, et al: Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13:2371-2380, 2002
63. BOHMIG GA, EXNER M, HABICHT A, et al: Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13:1091-1099, 2002
64. LORENZ M, REGELE H, SCHILLINGER M, et al: Risk factors for capillary C4d deposition in kidney allografts: Evaluation of a large study cohort. Transplantation 78:447-452, 2004
65. REGELE H, EXNER M, WATSCHINGER B, et al: Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 16:2058-2066, 2001
66. SIJPKENS YW, JOOSTEN SA, WONG M-C, et al: Immunological risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 65:2409-2418, 2004
67. LEDERER SR, KLUTH-PEPPER B, SCHNEEBERGER H, et al: Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 59:334-341, 2001
68. WORTHINGTON JE, MARTIN S, AL HUSSEINI DM, et al: Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 75:1034-1040, 2003
69. SUPON P, CONSTANTTNO D, HAO P, et al: Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 71:577-580, 2001
70. MARTIN L, GUIGNIER F, MOUSSON C, et al: Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 76:395-400, 2003
71. SUMITRAN-HOLGERSSON S, WILCZEK HE, HOLGERSSON J, et al: Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74:268-277, 2002
72. BALL B, MOUSSON C, RATIGNIER C, et al: Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplant Proc 32:353-354, 2000
73. JOOSTEN SA, VAN DIXHOORN MGA, BORRIAS MC, et al: Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 160:1301-1310, 2002
74. VAN DEN BORN J, VAN DEN HEUVEL LP, BAKKER MA, et al: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
75. JOOSTEN SA, SIJPKENS YW, VAN HAM V, et al: Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5:383-393, 2005
76. PAUL LC, VAN ES LA, STUFFERS-HEIMAN M, et al: Antibodies directed against tubular basement membranes in human renal allograft recipients. Clin Immunol Immunopathol 14:231-237, 1979
77. PAUL LC: Glomerular hypertension - An under-appreciated aspect of chronic rejection. Nephrol Dial Transplant 16:213-215, 2001
78. SANCHEZ-FRUCTUOSO AI, PRATS D, MARQUES M, et al: Does renal mass exert an independent effect on the determinants of antigen-dependent injury? Transplantation 71:381-386, 2001
79. GASTON RS, HUDSON SL, JULIAN BA, et al: Impact of donor/recipient size matching on outcomes in renal transplantation. Transplantation 61:383-388, 1996
80. POUTEIL-NOBLE C, MAIZA H, REMONTET L: Post-transplant glomerular filtration rate as a marker for long-term outcome. Ann Transplant 5:29-36, 2000
81. RANDHAWA PS, MINERVINI MI, LOMBARDERO M, et al: Biopsy of marginal donor kidneys: Correlation of histologic findings with graft dysfunction. Transplantation 69:1352-1357, 2000
82. OPPENHEIMER F, ALJAMA P, ASENSIO PEINADO C, et al: The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant (Suppl 3):11-15, 2004
83. HALLORAN PF, MELK A, BARTH C: Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 10:167-181, 1999
84. DE FIJTER JW, MALLAT MJ, DOXIADIS II, et al: Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 12:1538-1546, 2001
85. ROODNAT JI, ZIETSE R, MULDER PG, et al: The vanishing importance of age in renal transplantation. Transplantation 67:576-580, 1999
86. TERASAKI PI, CECKA JM, GJERTSON DW, et al: High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 333:333-336, 1995
87. HUMAR A, HASSOUN A, KANDASWAMY R, et al: Immunologic factors: The major risk for decreased long-term renal allograft survival. Transplantation 68:1842-1846, 1999
88. KNIGHT RJ, BURROWS L, BODIAN C: The influence of acute rejection on long-term renal allograft survival: A comparison of living and cadaveric donor transplantation. Transplantation 72:69-76, 2001
89. OPELZ G, WUJCIAK T, RITZ E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53:217-222, 1998
90. MANGE KC, CIZMAN B, JOFFE M, et al: Arterial hypertension and renal allograft survival. JAMA 283:633-638, 2000
91. COSIO FG, PELLETIER RP, SEDMAK DD, et al: Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 56:1912-1919, 1999
92. VAN ES LA, SIJPKENS YW, PAUL LC: Surrogate markers of chronic allograft nephropathy. Ann Transplant 5:7-11, 2000
93. VATHSALA A, VERANI R, SCHOENBERG L, et al: Proteinuria in cyclosporine-treated renal transplant recipients. Transplantation 49:35-41, 1990
94. GUIJARRO C, MASSY ZA, KASISKE BL: Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int (Suppl 52):S56-S59, 1995
95. ROODNAT JI, MULDER PG, ZIETSE R, et al: Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 69:1704-1710, 2000
96. WISSING KM, ABRAMOWICZ D, BROEDERS N, et al: Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 70:464-472, 2000
97. BOSMANS JL, HOLVOET P, DAUWE SE, et al: Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 59:2346-2356, 2001
98. ORTH SR, RITZ E, SCHRIER RW: The renal risks of smoking. Kidney Int 51:1669-1677, 1997
99. SUNG RS, ALTHOEN M, HOWELL TA, et al: Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 71:1752-1757, 2001
100. PRATSCHKE J, WILHELM MJ, LASKOWSKI I, et al: Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 12:2474-2481, 2001
101. TAKADA M, NADEAU KC, HANCOCK WW, et al: Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 65:1533-1542, 1998
102. GASSER M, WAAGA AM, KIST-VAN HOLTE JE, et al: Normalization of brain death-induced injury to rat renal allografts by recombinant soluble P-selectin glycoprotein ligand. J Am Soc Nephrol 13:1937-1945, 2002
103. WILHELM MJ, PRATSCHKE J, LASKOWSKI I, et al: Ischemia and reperfusion injury. Transplant Rev 17:140-157, 2003
104. DRAGUN D, HOFF U, PARK JK, et al: Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 58:2166-2177, 2000
105. DAEMEN MA, DE VRIES B, BUURMAN WA: Apoptosis and inflammation in renal reperfusion injury. Transplantation 73:1693-1700, 2002
106. TULLIUS SG, NIEMINEN M, BECHSTEIN WO, et al: Contribution of early acute rejection episodes to chronic rejection in a rat kidney retransplantation model. Kidney Int 53:465-472, 1998
107. GJERTSON DW: A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS Update. Clin Transplant 10:343-360, 1996
108. SIENKO J, WISNIEWSKA M, OSTROWSKI M, et al: Factors that impact on immediate graft function in patients after renal transplantation. Transplant Proc 35:2153-2154, 2003
109. SERRANO M, BLASCO MA: Putting the stress on senescence. Curr Opin Cell Biol 13:748-753, 2001
110. LINSKENS MH, FENG J, ANDREWS WH, et al: Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res 23:3244-3251, 1995
111. DIMRI GP, LEE X, BASILE G, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363-9367, 1995
112. KURZ DJ, DECARY S, HONG Y, et al: Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113:3613-3622, 2000
113. ROBLES SJ, ADAMI GR: Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16:1113-1123, 1998
114. MELK A, RAMASSAR V, HELMS LM, et al: Telomere shortening in kidneys with age. J Am Soc Nephrol 11:444-453, 2000
115. MELK A, SCHMIDT BM, TAKEUCHI O, et al: Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 65:510-520, 2004
116. MELK A, KITTIKOWIT W, SANDHU I, et al: Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. Kidney Int 63:2134-2143, 2003
117. XU B, SAKKAS LI, SLACHTA CA, et al: Apoptosis in chronic rejection of human cardiac allografts. Transplantation 71:1137-1146, 2001
118. DING G, FRANKI N, KAPASI AA, et al: Tubular cell senescence and expression of TGF-betal and p21(WAF1/CIP1) in tubulointerstitial fibrosis of aging rats. Exp Mol Pathol 70:43-53, 2001
119. CHKHOTUA AB, ALTIMARI A, GABUSI E, et al: Increased expression of p21 (WAF1/CIP1) cyclin-dependent kinase (CDK) inhibitor gene in chronic allograft nephropathy correlates with the number of acute rejection episodes. Transplant Int 16:502-506, 2003
120. CHKHOTUA AB, GABUSI E, ALTIMARI A, et al: Increased expression of p16 and p27 cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy. Am J Kidney Dis 41:1303-1313, 2003
121. FERLICOT S, DURRBACH A, BA N, et al: The role of replicative senescence in chronic allograft nephropathy. Hum Pathol 34:924-928, 2003
122. JOOSTEN SA, VAN HAM V, NOLAN CE, et al: Telomere shortening and cellular senescence in a model of chronic renal allograft rejection. Am J Pathol 162:1305-1312, 2003
123. VON ZGLINICKI T: Oxidative stress shortens telomeres. Trends Biochem Sci 27:339-344, 2002
124. RAMIREZ R, CARRACEDO J, JIMENEZ R, et al: Massive telomere loss is an early event of DNA damage-induced apoptosis. J Biol Chem 278:836-842, 2003
125. MORRIS PJ, JOHNSON RJ, FUGGLE SV, et al: Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UK-TSSA). Lancet 354:1147-1152, 1999
126. DUQUESNOY RJ: HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 63:339-352, 2002
127. PASCUAL M, THERUVATH T, KAWAI T, et al: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346:580-590, 2002
128. SCHOLTEN EM, DE FIJTER JW, PAUL LC: Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy. Curr Drug Targets Cardiovasc Haematol Disord 2:79-96, 2002
129. SARWAL M, CHUA MS, KAMBHAM N, et al: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349:125-138, 2003
130. GEBAUER BS, HRICIK DE, ATALLAH A, et al: Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2:857-866, 2002
131. MAUIYYEDI S, COLVIN RB: Humoral rejection in kidney transplantation: New concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 11:609-618, 2002
132. MATHEW TH: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65:1450-1454, 1998
133. MARGREITER R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 359:741-746, 2002
134. MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM, et al: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75:1341-1346, 2003
135. MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM, et al: Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3:68-73, 2003
136. KAHAN BD, JULIAN BA, PESCOVITZ MD, et al: Srrolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 68:1526-1532, 1999
137. NASHAN B: Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 11:1845-1857, 2002
138. MOSES JW, LEON MB, POPMA JJ, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003
139. FELLSTROM B: Cyclosporine nephrotoxicity. Transplant Proc 36:220-223, 2004
140. MCALISTER VC, GAO Z, PELTEKIAN K, et al: Sirolimus-tacrolimus combination immunosuppression. Lancet 355:376-377, 2000
141. FORMICA RN, LORBER KM, FRIEDMAN AL, et al: The evolving experience using everolimus in clinical transplantation. Transplant Proc 36:495-499, 2004
142. RANDHAWA PS, TSAMANDAS AC, MAGNONE M, et al: Microvascular changes in renal allografts associated with FK506 (tacrolimus) therapy. Am J Surg Pathol 20:306-312, 1996
143. MORRIS-STIFF GJ, BABOOLAL K, DUNSTAN F, et al: Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: Results of an observational study. Transplant Int 12:288-292, 1999
144. GLICKLICH D, GUPTA B, SCHURTER-FREY G, et al: Chronic renal allograft rejection: No response to mycophenolate mofetil. Transplantation 66:398-399, 1998
145. REMUZZI G, LESTI M, GOTTI E, et al: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet 364:503-512, 2004
146. MEIER-KRIESCHE H, OJO AO, ARNDORFER JA, et al: Mycophenolate mofetil decreases the risk for chronic renal allograft failure. Transplant Proc 33:1005-1006, 2001
147. MERVILLE P, BERGE F, DEMINIERE C, et al: Lower incidence of chronic allograft nephropathy at 1 year post transplantation in patients treated with mycophenolate mofetil. Am J Transplant 4:1769-1775, 2004
148. WEIR MR, WARD MT, BLAHUT SA, et al: Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59:1567-1573, 2001
149. THERUVATH TP, SAIDMAN SL, MAUIYYEDI S, et al: Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 72:77-83, 2001
150. CALVINO J, LENS XM, ROMERO R, et al: Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 15:82-86, 2000
151. LIN J, VALERI AM, MARKOWITZ GS, et al: Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 73:783-788, 2002
152. FEEHALLY J, HARRIS KP, BENNETT SE, et al: Is chronic renal transplant rejection a non-immunological phenomenon? Lancet 2:486-488, 1986
153. HOLDAAS H, JARDINE A: Acute renal allograft rejections, a role for statins? Minerva Urol Nefrol 55:111-119, 2003